-+ 0.00%
-+ 0.00%
-+ 0.00%

T-THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $133 MILLION SERIES B FINANCING TO ACHIEVE CLINICAL PROOF-OF-CONCEPT FOR FIRST-IN-CLASS TCR BISPECIFIC THERAPIES IN CANCER AND AUTOIMMUNE DISEASE

Reuters·11/05/2026 07:15:17

Please log in to view news